Publications

Publications

Filter Results: (20) Arrow Down

Show Results For

Page 1 of 20 Results
  • January 2018
  • Article

Innovation Incentives and Biomarkers

By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
Previously, we have discussed the importance of economic incentives in shaping markets for precision medicines. Here we consider incentives for biomarker development, including discovery and establishment. Biomarkers can reveal valuable information regarding diagnosis... View Details
Keywords: Health Care and Treatment; Innovation and Invention; Research and Development; Markets
Related
  • Article

Managing the Use and Dissemination of Information about Biomarkers: The Importance of Incentive Structures.

By: Ariel Dora Stern
The use of biomarkers holds great promise for the development of new therapeutics and the acceleration of clinical research. However, biomarkers must be validated—a complex and costly endeavor. Importantly, biomarker validation is meaningfully shaped by economic and... View Details
Keywords: Biomarkers; Information Management; Health Care and Treatment; Motivation and Incentives
Related
  • 11 Apr 2017
  • First Look

First Look at New Research, April 11

Alexander, and Amitabh Chandra Abstract—Many public and private efforts in coming years will focus on research in precision medicine, developing biomarkers to indicate which patients are likely to benefit from a certain treatment so that... View Details
  • March 17, 2017
  • Article

How Economics Can Shape Precision Medicines

By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
Many public and private efforts in coming years will focus on research in precision medicine, developing biomarkers to indicate which patients are likely to benefit from a certain treatment so that others can be spared the cost—financial and physical—of being treated... View Details
Keywords: Health Care and Treatment; Research; Economics; Motivation and Incentives
Related
  • March 2021
  • Article

Provider Teams Outperform Solo Providers in Managing Chronic Diseases and Could Improve the Value of Care

By: Maximilian J. Pany, Lucy Chen, Bethany Sheridan and Robert S. Huckman
Scope-of-practice regulations, including prescribing limits and supervision requirements, may influence the propensity of providers to form care teams. Therefore, policy makers need to understand the effect of both team-based care and provider type on clinical... View Details
Keywords: Disease Management; Team-based Care; Health Care and Treatment; Groups and Teams; Performance
Related
  • 2018
  • Chapter

The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century

By: Nicholas Bagley, Benjamin Berger, Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
On the 35th anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormous changes in the markets for therapies for rare diseases that have emerged over recent decades. The most prominent example is the fact that the profit-maximizing price of new... View Details
Keywords: Health Care and Treatment; Laws and Statutes; Research and Development; Investment; Markets; Monopoly
Related
  • Web

Curriculum - MBA

and in establishment of novel therapeutic approaches and biomarkers to guide treatment. Principles of Human Disease: Physiology and Pathology This course covers the normal physiology and pathophysiology of selected organs. Human biology... View Details
  • 01 Jun 2023
  • News

From Big Pharma to Startup

Hunter Goble (MBA 2022) did not enroll in Harvard Business School with dreams of becoming an entrepreneur. After earning his MBA, Goble intended to return to Eli Lilly to continue to work building brands and launching products. He envisioned himself leading a big,... View Details
Keywords: April White
  • 16 Sep 2016
  • News

Gaining Ground on ALS

1998. “But this grant is significant because it facilitates the sharing of plasma samples, collected from test subjects over time, with academic researchers.” The collaboration is a first for an international, late-stage trial and could help identify View Details
  • Profile

Arjun Goyal

truly global, and in entrepreneurship, it’s not just limited to software.” In business, in action, in the i-lab Arjun has already applied the HBS network and resources to his own enterprise, Foresight Pharmaceuticals, a start-up dedicated to “personalized medicine”:... View Details
Keywords: Entrepreneurship; Health Care
  • Profile

Arjun Goyal

global, and in entrepreneurship, it’s not just limited to software.” In business, in action, in the i-lab Arjun has already applied the HBS network and resources to his own enterprise, Foresight Pharmaceuticals, a startup dedicated to “personalized medicine”: the... View Details
  • 31 Oct 2017
  • First Look

New Research and Ideas, October 31, 2017

Potential of Patient-Reported Outcomes By: Rotenstein, Lisa, Robert S. Huckman, and Neil Wagle Abstract—No abstract available. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=53372 forthcoming Clinical Pharmacology & Therapeutics Innovation... View Details
Keywords: by Sean Silverthorne
  • Web

Kraft Accelerator

The Clinical Trial of the Future? HBS Case Collection Innovative Incentives and Biomarkers HBS Case Collection Investment Cases Dementia Discovery Fund HBS Case Collection Impact Investing Could Accelerate the Fight Against Cancer HBS... View Details
  • 01 Jan 2008
  • News

Jeffrey R. Immelt, MBA 1982

protein biomarkers that have been identified as the precursor to Alzheimer’s disease. “There’s still no cure,” he observes, “but if you know that someone has the early signs of the disease and combine that with some of the new drugs the... View Details
  • 13 Oct 2016
  • News

Adding Muscle to the Fight Against Disease

included in a late-stage trial a component that is publicly available,” explains Blum. He notes that studies of the samples by independent researchers could help identify biomarkers for the disease’s causes and progression. Not Just... View Details
Keywords: Deborah Blagg
  • 20 Aug 2014
  • News

With No Time to Lose

other than Kremer’s adopted Prize4Life for their charity auctions and students across Harvard University took up the cause. A game-changer Since then, Prize4Life has accomplished many of its goals. In 2011, it awarded its first $1M ALS View Details
Keywords: Margie Kelley
  • 05 Nov 2014
  • What Do You Think?

Are We Entering an Era of Neuromanagement?

participants with higher gray matter volume in this region exhibited less risk aversion. The results "identify what might be considered the first stable biomarker for financial risk-attitude," according to the authors. The study... View Details
Keywords: by James Heskett
  • 18 Dec 2018
  • First Look

New Research and Ideas, December 18, 2018

firms face little competition, even after the end of formal periods of patent protection and market exclusivity. Additionally, the evolving technologies of drug development—in particular, the increasingly common use of auxiliary endpoints in clinical trials and the use... View Details
Keywords: Dina Gerdeman
  • 01 Dec 2013
  • News

Curing Health Care

products. Stock predicts that the development pace for personalized therapeutics and preventive diagnostics will pick up speed, thanks to the beneficial add-on effects derived from identifying more and more biomarkers for particular... View Details
Keywords: Ambulatory Health Care Services; Health, Social Assistance; Management; Colleges, Universities, and Professional Schools; Educational Services